Literature DB >> 32573923

Nasopharyngeal carcinoma in children and young adults-Beyond 5-year survival.

Tal Ben-Ami1, Shifra Ash2, Miri Ben-Harosh3, Herzel Gavriel4, Michael Weintraub5, Shoshana Revel-Vilk6, Myriam Ben-Arush7.   

Abstract

Nasopharyngeal carcinoma (NPC) is a rare and locally aggressive form of childhood cancer. Treatment of NPC includes chemotherapy and radiotherapy. With current treatment protocols, survival rates for patients with nonmetastatic disease is over 80%. Data regarding very late events including long-term treatment-related morbidities and second malignancies are scarce. We present our data on 42 patients with NPC treated in Israel between 1989 and 2014, and followed until 2019. During follow up, five patients had disease recurrence, and four children developed secondary malignancy. Median time to diagnosis of secondary malignancy was 105 months. Eighty-eight percent of patients have long-term treatment-related morbidities.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  late toxicities; long-term follow up; nasopharyngeal carcinoma; second malignancies

Year:  2020        PMID: 32573923     DOI: 10.1002/pbc.28494

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  1 in total

1.  Circular RNA SET domain protein 3 promotes nasopharyngeal carcinoma proliferation, cisplatin resistance, and protein kinase B / mammalian target of rapamycin pathway activation by modulating microRNA-147a expression.

Authors:  Gang Deng; Fei Wang; YiSa Song
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.